Granules India Ltd (GRANULES)
₹833.55
Mkt cap
₹20,655 Cr
P/E ratio
31.80
P/B
4.07
Div yield
0.21%
ROE
13.80%
ROCE
15.50%
EPS (TTM)
₹26.21
Book value
₹205
52W range
439–903
Sector
Healthcare
Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages. [1]
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−7.72% from high₹834
₹439+89.72% from low₹903
Current
₹833.55
Prev close
₹835.00
Day
−0.17%
Price performance
1D
−0.17%
1W
−4.86%
1M
+9.07%
3M
+20.90%
6M
+50.80%
1Y
+65.90%
YTD
+35.46%
Financials
FRevenue, profit & margin
P/E ratio
31.8×
GRANULES is 7% below the sector median of 34.0×
GRANULES31.8×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 986 | 1,189 | 1,156 | 1,176 | 1,180 | 967 | 1,138 | 1,197 | 1,210 | 1,297 | 1,388 | 1,471 | 1,477 | |
| Expenses | 849 | 977 | 905 | 920 | 921 | 763 | 907 | 945 | 963 | 1,019 | 1,080 | 1,119 | 1,138 | |
| Operating Profit | 137 | 213 | 250 | 256 | 259 | 203 | 230 | 252 | 247 | 278 | 308 | 352 | 339 | |
| OPM % | 14% | 18% | 22% | 22% | 22% | 21% | 20% | 21% | 20% | 21% | 22% | 24% | 23% | |
| Other Income | 0 | 2 | 1 | 2 | 2 | 3 | 6 | 33 | -10 | -1 | -4 | 25 | 2 | |
| Interest | 22 | 26 | 29 | 29 | 27 | 26 | 27 | 24 | 24 | 29 | 29 | 33 | 21 | |
| Depreciation | 49 | 53 | 52 | 53 | 53 | 53 | 57 | 64 | 69 | 72 | 74 | 82 | 80 | |
| Profit before tax | 65 | 136 | 170 | 176 | 181 | 128 | 153 | 198 | 145 | 176 | 202 | 262 | 240 | |
| Tax % | 27% | 25% | 26% | 26% | 26% | 24% | 23% | 23% | 22% | 26% | 26% | 23% | 25% | |
| Net Profit | 48 | 102 | 126 | 130 | 135 | 97 | 118 | 152 | 113 | 131 | 150 | 202 | 180 | |
| EPS in Rs | 1.98 | 4.21 | 5.18 | 5.35 | 5.56 | 4.01 | 4.85 | 6.27 | 4.64 | 5.38 | 6.19 | 8.13 | 7.26 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.47% · closed higher next day 21 of last 58
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23◦ | 23 Jan '24 | 15 May '24◦ | 30 Jul '24 | 6 Nov '24◦ | 24 Jan '25 | 28 May '25 | 12 Aug '25 | 13 Nov '25 | 23 Jan '26◦ | 29 Apr '26 | 21 Jul '26 |
| Earnings day | −0.96% | −1.09% | +0.79% | +4.27% | −0.75% | −2.94% | −1.21% | +3.30% | +2.55% | +2.50% | −0.09% | −0.05% |
| +1 day | −0.31% | +0.13% | +1.30% | +11.55% | +1.40% | −9.17% | +1.23% | +4.49% | +1.06% | −0.02% | −0.77% | −2.55% |
| +5 days | −0.80% | −0.18% | +8.23% | +14.90% | −7.38% | −7.21% | −0.27% | +4.72% | +1.54% | +1.20% | +5.44% | — |
| +15 days | +5.13% | +3.70% | +18.02% | +22.97% | +3.23% | −9.56% | −6.41% | +16.41% | +4.42% | +0.67% | +8.37% | — |
| +30 days | +7.39% | +10.09% | +24.19% | +19.80% | +1.78% | −17.75% | −9.31% | +20.34% | +13.81% | +3.75% | +8.69% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 1.75 Per Share | 1.75 | 30 Jul '26 | 30 Jul '26 |
Results analysis
Shareholding
Sas of Jun 202638.01%Promoter
Promoters38.01%0.01
FIIs17.50%2.19
DIIs16.11%0.90
Public28.36%1.31
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Granules India | ₹833.55 | 31.77 | 20,655 | 0.21% | 180 | +36.62% | 1,477 | +22.04% | 15.51% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts86
PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026PPTApr 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptJan 2025PPTJan 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 2d - Q1 FY27 earnings conference call audio recording uploaded on company website.Announcement under Regulation 30 (LODR)-Monitoring Agency Report 21 Jul - Q1 FY27 monitoring report shows ₹665.63 crore preferential issue proceeds raised, with no deviationobjects.Announcement under Regulation 30 (LODR)-Investor Presentation 21 JulAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 21 Jul - Q1FY27 revenue rose 22% to INR 14,768 Mn; PAT up 60% to INR 1,800 Mn.Board Meeting Outcome for Outcome Of The Board Meeting Dated July 21, 2026 21 Jul - Board approved Q1 FY27 results on July 21, 2026; consolidated revenue ₹14,767.74 million, profit ₹1,799.63 million.